bluebird bio (BLUE) to Present New Data from Three LentiGlobin Studies at ASH
- S&P 500 closes higher to secure strongest Q1 since 2019
- UBS sees 5 warnings signals on semiconductor chip stocks
- US consumer sentiment tops estimates in March to hit nearly 3-yr high, UMich says
- Reddit (RDDT) stock continues to slide as short-sellers eye stock
- Estée Lauder (EL) climbs as BofA upgrades to Buy on profit recovery expectations
- AMC Entertainment (AMC) enters into an equity distribution agreement
- Kerrisdale Capital is short Microstrategy (MSTR), long bitcoin
- AMC Entertainment (AMC) Enters $250M ATM Agreement
- Intuitive Machines (LUNR) Files for $300M Share Offering, 160M Share Offering by Selling Stockholders
- Home Depot (HD) to Acquire SRS Distribution for $18.25B EV
bluebird bio to Present New Data from Three LentiGlobinTM Clinical Studies at American Society of Hematology (ASH) Annual Meeting
November 3, 2016 9:01 AM EDTData from the Northstar (HGB-204) study of LentiGlobin drug product in transfusion-dependent -thalassemia (TDT) show that all five patients with non-0/0 genotypes and 12 months of follow-up remained free of transfusions, and patients with 0/0 genotypes and 12 months of follow-up (n=5) had a median reduction in transfusion volume of 60%
The median HbAT87Q level at six months in Northstar was 4.7 g/dl across all genotypes, and levels were generally sustained over the second year of follow-up
All patients with TDT from the HGB-205 study remained free of transfusions,... More